Indometacin

The global market demand for non-steroidal anti-inflammatory drugs continues to rise. Among the clinical medication options for chronic pain and inflammation, indomethacin is one of the classic and widely used categories. As a cyclooxygenase (COX) inhibitor, it exerts rapid antipyretic, analgesic and anti-inflammatory effects by inhibiting prostaglandin synthesis. Clinically, it is mostly used to relieve the joint swelling and pain symptoms of rheumatoid arthritis, acute attack of gouty arthritis and ankylosing spondylitis, and can also be used for symptomatic treatment of acute pain such as postoperative pain and migraine. The applicable population covers adult patients with chronic inflammatory diseases and people with acute pain attacks, and it is a commonly used basic drug in primary medical institutions and specialist treatment.

Public data show that in recent years, the domestic market size of indomethacin API has stabilized in the range of 320 million to 380 million yuan, with a compound annual growth rate of about 4.1%. The demand growth mainly comes from the penetration of primary diagnosis and treatment scenarios and the R&D expansion of external preparations and compound preparations. At present, the domestic supply pattern is dominated by local generic pharmaceutical enterprises, with the top 3 enterprises occupying nearly 70% of the market share. With the expansion of production capacity on the preparation side after the implementation of centralized procurement, the compliance demand for upstream API and corresponding impurity reference standards continues to rise. At present, there is no publicly verifiable segmented growth rate data for the global market.

CATO provides a full set of impurity reference standards for indomethacin API. All products meet the quality requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. With sufficient in-stock inventory available for direct delivery, it can quickly provide compliance support for API enterprises, preparation R&D institutions and quality inspection departments, shorten the R&D and quality research cycle, and meet the full-scenario needs of declaration and daily quality control.